Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: AMRN

Amarin Corporation plc

Healthcare | Biotechnology

No licensed closing price on file for AMRN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.07

Amarin Corporation plc (NASDAQ: AMRN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 09:57 UTC.

What Amarin Corporation plc does

Amarin Corporation plc is a pharmaceutical company that develops and commercializes therapeutics focused on cardiovascular health and reducing cardiovascular risk. The company's main product is VASCEPA (icosapent ethyl), which was approved by the U.S. FDA in July 2012 for reducing triglyceride levels in patients with severe hypertriglyceridemia, and received a second FDA approval in December 2019 for reducing cardiovascular risk in high-risk patients on statin therapy.

Summarized from Amarin Corporation plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.07

Revenue, margins & earnings

FY2021 Net income: $8MFY2021 Operating expenses: $451MFY2021 Cost of revenue: $121M$583MFY2021FY2022: net loss $106M on revenue $369M$369MFY2022FY2023: net loss $59M on revenue $307M$307MFY2023FY2024: net loss $82M on revenue $229M$229MFY2024FY2025: net loss $39M on revenue $214M$214MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-03
  • 2026-08-03SVP, CFOTax withholding-155$2.2K
  • 2026-08-03SVP, CFORestricted Stock UnitAward313—
  • 2026-08-03SVP, CFOOption exercise313—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Amarin Corporation plc do?

Amarin Corporation plc is a pharmaceutical company that develops and commercializes therapeutics focused on cardiovascular health and reducing cardiovascular risk.

When did AMRN last file with the SEC?

Amarin Corporation plc's most recent SEC filing on record is a SCHEDULE 13D/A filed 2026-08-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 09:57 UTC. This page is also available as JSON at /api/data?ticker=AMRN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for AMRN and 5,000+ tickers.

Create a free account — keep AMRN
For your agent
GET /api/data?ticker=AMRN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt